12/4/2018, Tuesday
Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683
Laser to be Developed Specifically for Use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection)
BRIDGEWATER, N.J., Dec. 4, 2018 – Bausch + Lomb, a leading global eye health company, and Modulight, Inc., a designer and manufacturer of lasers and optics for personalized medicine, today announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT).
“PDT continues to be an important option for eye care professionals who treat choroidal neovascularization in patients who suffer from persistent disease activity, but the availability of lasers capable of delivering this type of treatment in the industry has been limited,” said Tracy Valorie, senior vice president and general manager, U.S. Pharmaceuticals and Surgical, Bausch + Lomb. “We have entered this agreement with Modulight, an industry expert in developing medical laser technology, to provide customers a new laser system that is specifically designed for VISUDYNE and ultimately will allow more eligible patients to receive the treatment they need.”
VISUDYNE is an injectable photosensitizer drug that is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. VISUDYNE is activated through use of a photodynamic laser via direct laser excitation, delivering a targeted approach that specifically destroys abnormal choroidal blood vessels to help prevent further disease progression and help patients maintain their vision.¹
“Modulight works closely with healthcare companies to customize its broad portfolio of laser technology solutions to specifically address their needs,” said Seppo Orsila, executive chairman, Modulight.
“Bausch + Lomb has identified a significant need in the ophthalmic industry and we believe this is a great opportunity to develop a state-of-the-art photodynamic laser to allow customers to continue to provide this type of therapy for their patients. We look forward to a strong promising collaboration."
INDICATION
Visudyne® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
IMPORTANT SAFETY INFORMATION
Please see full Prescribing Information for Visudyne® (location) or Click here for full Prescribing Information for Visudyne®
About Modulight
Modulight, Inc. is a leading biomedical laser company for genetics, oncology, and ophthalmology. Modulight products are used by many pharmaceutical companies as well as leading cancer centers in the world to cure, develop, and diagnose the most demanding indications and therapies. While the majority of Modulight’s products are sold in the United States, the company is proud of their loyal customer base spanning over the entire globe. Modulight’s support extends beyond the hardware – every week Modulight lasers are installed, trained and calibrated in various hospitals around the world. Visit www.modulight.com for more information.
About Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.
References
1. VISUDYNE [package insert], Bausch & Lomb Incorporated.
###
VISUDYNE is a registered trademark of Novartis AG used under license. Any other product/brand names are trademarks of the respective owners. © 2018 Bausch & Lomb Incorporated. VID.0040.USA.18
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.